Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Fig. 1

Surface GRP78 expression in PBMC subpopulations. GRP78 expression was determined by FACS in 15 different PBMC subpopulations at three time points in the neoadjuvant setting: P1 (prior to any treatment), P2 (after the AC phase), and P3 (after taxane phase). Mean cell surface expression of GRP78 was compared among different PBMC sub-populations using one-way ANOVA and Tukey tests. a T cell subpopulations; b T memory cells; c natural killer cells; d monocytes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us